Drug Profile

Lead 212 BT 1702

Alternative Names: ²¹²Pb BT 1702; BT1702; MT1-MMP BRC

Latest Information Update: 20 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bicycle Therapeutics
Class Diagnostic agents; Imaging agents; Peptide drug conjugates; Radioisotopes; Radiopharmaceutical diagnostics
Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

31 Mar 2026 Bicycle Therapeutics plans first in human clinical trial for Lead 212 BT 1702 in 2027 (Bicycle Therapeutics pipeline, March 2026)
31 Mar 2026 Preclinical trials in Cancer (Diagnosis) in USA (unspecified route)
31 Mar 2026 Preclinical trials in Cancer in USA (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com